Published August 5, 2026 | Version v1

Dataset: Hypothesis: Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging - PathMap Experiment #000100

Authors/Creators

  • 1. Artificial General Intelligence LLC
  • 1. Artificial General Intelligence LLC

Description

Interactive Data Viewer: Read, View, and Print from Day 1

Use our fully interactive viewer to view, read, and print this research data right from Day 1:
https://pathmap.org/viewer.php?id=100


Artificial General Intelligence LLC

Claim Evaluated: Hypothesis: Restored clearance of senescent neutrophils by tissue-resident macrophages limits organ aging

This dataset contains the raw JSON execution trace, verified verbatim quotes, and MeSH-aligned logic gates generated by PathMap Studio's Veridical Enforcement engine.


🔍 Novel & Overlooked Insights

  • Erythroblasts in the bone marrow act as a key regulatory niche by generating specialized pro-resolving mediators (SPMs) that instruct neutrophil development and prevent premature senescent-like functional shifts.
  • The accumulation of senescent cells, such as vascular smooth muscle cells (VSMCs), generates a senescence-associated secretory phenotype (SASP) that creates a "don't-eat-me" environment, directly disrupting macrophage efferocytosis in atherosclerosis.
  • The "charge-sensitive" recognition mechanism, modulated by pH and cationic molecules, reveals that the microenvironment itself acts as a regulatory checkpoint for neutrophil clearance, independent of classical receptor-ligand interactions.
  • NETs (Neutrophil Extracellular Traps) not only promote inflammation but also actively inhibit efferocytosis by cleaving macrophage surface integrins like αvβ3 and αvβ5, creating a feedback loop of persistent cellular debris.
  • The metabolic state of the macrophage, particularly mitochondrial health and ROS-sensing pathways (e.g., DRP1 sulfenylation, AMPK phosphorylation), is an intrinsic requirement for the successful resolution of neutrophil-driven injury.
  • Commensal-derived metabolites, such as indole-3-acetaldehyde, provide a microbiome-host axis that enhances macrophage phagocytosis via PXR/NRF2 signaling, suggesting that the lung microbiome is a modulator of efferocytic efficiency.
  • The failure of "resolution programs" in disease is more significant than the failure of "anti-inflammatory" pathways, as evidenced by the failure of traditional anti-inflammatory drugs in clinical settings.
  • Small-molecule TKIs, like neratinib, possess previously unrecognized pro-resolving properties, offering a repurposing opportunity to restore MerTK-mediated efferocytosis in multimorbid patients.
  • The transition from monocyte to tissue-resident macrophage requires the enzyme deoxyhypusine synthase (DHPS).
  • Cardiac resident macrophages rely on Maresin 1 (MaR1) signaling, which binds to PPARγ to induce CD204 expression, an efferocytosis-related target.
  • The pentose phosphate pathway (PPP) is preferentially activated in resident thymic macrophages to manage the reduction-oxidation stress associated with efferocytosis.
  • Systemic iron homeostasis and complement regulation, influenced by Tregs in the brain, also utilize efferocytosis-related receptors like MERTK and AXL.
  • Microbiome modulation, including probiotics like *L. plantarum* and *L. reuteri*, can alter tryptophan metabolism (e.g., indole derivatives) to promote an anti-inflammatory state.
  • The "interferon gap" in the elderly can be mitigated by mucosal Th1-Trm activation, proving that the mucosal immune reservoir is highly dynamic.
  • Nano-bio interfaces, such as PET nanoplastic protein coronas, can pathologically rewire macrophage efferocytosis to facilitate tumor immune evasion.

🧪 Extracted Custom Datapoints

📊 Suggested Experiments

  • Assess if pharmacological targeting of the charge-sensitive recognition mechanism (using cationic modulators) enhances neutrophil clearance in an aged mouse model.
  • Determine if systemic administration of resolvin D5 (n-3 DPA) derived from erythroblasts can rejuvenate the peripheral macrophage efferocytic phenotype in aged organisms.
  • Evaluate if inhibiting NETs using DNase I in aged models restores the CD36/MerTK signaling axis in tissue-resident macrophages.
  • Assess if aerosolized IAAld treatment in aged mice reduces serum markers of systemic inflammation.
  • Evaluate the impact of FMT from young to aged mice on alveolar macrophage efferocytic gene expression profiles.
  • Measure systemic insulin sensitivity following targeted pulmonary AM efferocytosis restoration in diabetic murine models.

📊 Suggested Studies

  • Longitudinal analysis of human patient cohorts to correlate systemic efferocytosis efficiency with biological markers of aging (e.g., epigenetic clocks).
  • Cross-species study on the evolution of efferocytosis efficiency relative to longevity across long-lived and short-lived mammals.
  • Investigation of the gut-lung axis in regulating efferocytosis via microbial metabolites in age-related respiratory declines.
  • Longitudinal cohort analysis of respiratory commensal metabolites in healthy vs. accelerated aging populations.
  • Spatial transcriptomics investigation of pulmonary macrophages in age-related frailty, focused on efferocytic receptor density.
  • Meta-analysis of microbiome-targeted therapies and their impact on systemic inflammatory biomarkers (CRP/IL-6) in patients.

📊 Swansons Literature Based Discovery Candidates

  • Enhancement of erythroblast-derived Resolvin D5 (RvD5n-3 DPA) signaling may ameliorate age-associated cognitive decline by normalizing the microglia-driven efferocytic resolution program.
  • Erythroblast-derived Resolvin D5 (RvD5n-3 DPA) imprints neutrophil development and function (ID: 42519831).
  • Reducing TRM EP2 signaling (which coordinates TRM function) limits cognitive decline in aged mice (ID: 42462036).
  • Microglia/Brain-resident macrophages as the common cell type (specialized tissue-resident macrophages).
  • Since erythroblasts imprint systemic granulopoiesis and tissue-resident macrophage status, and tissue-resident macrophages in the brain coordinate cognitive decline, increasing local pro-resolving lipid mediator signaling (like RvD5) may modulate the resident immune cell niche in the brain, thereby mimicking the cognitive-sparing effects of EP2 signaling inhibition.
  • Indole-3-acetaldehyde (IAAld) acts as a potential therapeutic agent for age-related cardiac remodeling by modulating the cardiac resident macrophage (CRM) efferocytosis axis.
  • IAAld as a metabolite of R. mucilaginosa enhances AM phagocytosis via PXR/NRF2 (ID 41715099).
  • CRM efferocytosis promotes myocardial I/R resolution and reduces fibrosis (ID 41554295).
  • PPAR-γ and NRF2 pathway integration in macrophage metabolism and inflammatory resolution.
  • Both NRF2 and PPAR-γ converge on metabolic reprogramming of macrophages to improve efferocytic efficiency; IAAld-mediated activation of the PXR/NRF2 axis in AMs may be applicable to CRMs to mitigate age-related myocardial fibrosis.

📊 Contradictions Between Evidences

  • While most evidence points to increased inflammation and impaired efferocytosis in aging, ID: 18467696 notes that adult mice show an early and acute 'cytokine storm' that is more lethal than in young mice, while ID: 18387441 reports suppressed inflammation and delayed granulation tissue in senescent hearts following injury. This suggests a context-dependent resolution dysfunction rather than simple 'inflamm-aging'.
  • None identified in the current set; all sources consistently link macrophage efferocytic dysfunction to pathology.

📊 Repurposed Solutions

  • Neratinib (an ErbB tyrosine kinase inhibitor) can be repurposed as an immunoresolvent to restore MerTK expression and efferocytosis in chronic inflammatory diseases (ID: 41857730). Additionally, Fucoidan can be utilized to activate the Gas6/MerTK pathway to reduce neuroinflammation (ID: 41351868).
  • Probiotics/postbiotics designed for gut-lung axis modulation (like L. lactis or Mn-CDs) could be repurposed for cardiac or hepatic repair by leveraging common efferocytic pathways.

📊 Lung Microbiome Axis

  • IAAld enhances RAMs/AMs phagocytosis, effectively clearing apoptotic neutrophils and LPS, which is crucial in aged tissues where efferocytic gene signatures are downregulated.

📊 Systemic Crosstalk

  • Restoration of TRM efferocytosis prevents the release of paracrine stress signals from the lung/liver, thereby dampening systemic inflammation and distal tissue damage in aged subjects.

📊 Metabolic Checkpoint

  • Yes, IAAld-mediated NRF2 nuclear translocation upregulates CD36, providing a metabolic checkpoint to restore phagocytic potential and mitochondrial fitness lost during aging.


Tags Attractor Table

Extracted Keywords & Entities
Aging, _gates_from_aging, Phagocytosis, _gates_to_phagocytosis, _gates_from_phagocytosis, Neutrophils, _gates_to_neutrophils, _gates_from_neutrophils, _gates_to_aging, Indoleacetic Acids, _gates_from_indoleacetic_acids, Pregnane X Receptor, _gates_to_pregnane_x_receptor, NF-E2-Related Factor 2, _gates_from_nf-e2-related_factor_2, Macrophages, Alveolar, _gates_to_macrophages,_alveolar, _gates_from_macrophages,_alveolar, Inflammation, _gates_to_inflammation

Run Your Own Analysis

PathMap is a patent-pending universal AI workbench designed to eliminate LLM hallucinations in medical research. Generate your own autonomous discovery reports at PathMap.org.

Notes

Patent Pending (U.S. Patent Application No. 64/084,252). Copyright 2026 Artificial General Intelligence LLC. All Rights Reserved.

Files

100.zip

Files (967.9 kB)

Name Size
md5:92ed5b19dc33f173f8531117f2219db5
967.9 kB Preview Download

Additional details

Related works